I really wish I did have as much influence here as you imply!you...

I really wish I did have as much influence here as you imply!
you seem to have some hotline to the ceo.
but you’re misconstruing what I said.
the primary endpoint is safety by the way.
yes secondary endpoints look at changes in who score but by uncontrolled what i mean is there is no standard of care only control arm to compare with veyonda plus standard of care.
an improvement in who score might well happen but you can’t definitively say it was due to veyonda because they might have improved with standard of care /other therapies given concurrently.
every other drug in c19 has had to eventually prove itself in randomised controlled trial eg remdesivir- success; dexa- success; hydroxychloroquine -fail. kaletra - fail. Veyonda will have to meet that bar, that’s all I’m saying. This trial NOXCOVID isn’t the definitive trial but it’s a good start
will provide lot of data to help design follow on definitive trial if that’s what Nox plans to do.
not Sure why any of this is controversial- or why you’re so defensive.